Present treatment and future expectations in advanced pancreatic cancer

Anticancer Research

Volumn 28, Issue 2 B, 2008, Pages 1303-1308

  Stathopoulos, George P ^a,c   Androulakis, Nikos ^b   Souglakos, John ^b   Stathopoulos, John ^a   Georgoulias, Vassilis ^b  

^a Errikos Dunant Hospital   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c NONE   (Greece)

Author keywords

Pancreatic cancer status; Review

Indexed keywords

CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RALTITREXED; RUBITECAN; TAXANE DERIVATIVE; TIPIFARNIB; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; ZANESTRA;

BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL GROWTH; CLINICAL TRIAL; GENE THERAPY; HUMAN; MONOTHERAPY; ONCOGENE RAS; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FORECASTING; HUMANS; PANCREATIC NEOPLASMS;

EID: 42549085643     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Brenna MF, Kinsella TJ and Casper ES: Cancer of the pancreas. In: Cancer, principles and practice of oncology. DeVita VT Jr, Hellman S, Rosenberg SA (eds.). 4th edition, Lippincott, Philadelphia, PA, pp. 849-882, 1993.
2. Schnall SF and Macdonald JS: Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 23: 220-228, 1996.
3. Stephens CD: Gemcitabine: a new approach to treating pancreatic cancer. Oncol Nurs Forum 25: 87-93, 1998.
4. Casper ES, Green MR and Kelsen DP: Phase II trial of gemcitabine (2.2 difluorodeoxytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12: 29-34, 1994.
5. Burris HJ HA, Moore MJ, Anderson J, Green HR, Rothenberg HL, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer, a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
6. Wagener DJ, Verdonk HE, Dirix LY, Catimel G, Siegenthaler P, Buitenhuis N, Mathieu-Boué A and Verweij J: Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 6: 129-132, 1995.
7. Scher RM, Kosierowski R, Lusch C, Alexander R, Fox S, Redei I, Green F, Raskay B, Amfoh K, Engstrom PF and O'Dwyer PJ: Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Invest New Drugs 13: 347-351, 1996.
8. Androulakis N, Kouroussis CH, Dimopoulos MA, Samelis G, Kakolyris S, Tsavaris N, Genatas K, Aravantinos G, Papadimitriou CR, Karabekios S, Stathopoulos GP and Georgoulias V: Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. J Clin Oncol 17: 1779-1785, 1999.
9. Rougier PH, Adenis A, Ducreux M, de Forni M, Bonneterre J, Dembak M, Clouet P, Lebecq A, Baille P, Lefresne-Soulas F, Blanc C and Armand JP: A phase II study of docetaxel as a first-line chemotherapy for advanced pancreatic carcinoma. Eur J Cancer 36: 1016-1021, 2000.
10. Konstandoulakis MM, Antonakis PT, Tsibloulis BG, Stathopoulos GP, Manouras AP, Mylonaki DB and Golematis BX: A phase II study of 9-nitro-camptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 48: 417-420, 2001.
11. Cartwright TH, Cohn A, Varkey JA, Chen Y-M, Szatrowski TP, Cox JV and Schulz JJ: A phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 20: 160-164, 2002.
12. Rothenberg ML, Sharm A, Weiss GR, Villanova-Calero MA, Eckardt JR, Aylesworfh C, Kraynak MA, Rinoldi DA, Rodrifuez GI, Burris III HA, Eckhardt SG, Stephens CS, Fovral K, Nicol SJ and Von Hoff DD: A phase I trial of paclitaxel and gemcitabine administered every 2 weeks in patients with refractory solid tumors. Ann Oncol 9: 733-738, 1998.
13. Bahadori HR, Rocha-Lima CM, Green MR and Safa AR: Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small-cell lung cancer cell lines. Anticancer Res 19: 5423-5428, 1999.
14. Hidalgo M, Castellano D, Paz-Ares L, Gravalos C, Diaz-Puente M, Hitt R, Alouso D and Cortes-Funes H: Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 17: 585-592, 1999.
15. Rocha-Lima CM, Leong SS, Sherman CA, Perkel JA, Putman-Hair T, Safa AR and Green MR: Phase I study of CPT-11 and gemcitabine in patients with solid tumors. Cancer Ther 2: 58-66, 1999.
16. Heinemann V, Wilke H, Mergenthaler HG, Clemens M, König H, Illiger HL, Arning M, Schalhorn A, Possinger K and Fink V: Gemcitabine and cisplatin in the treatment of advanced and metastatic pancreatic cancer: Ann Oncol 11: 1399-1403, 2000.
17. Stathopoulos GP, Mavroudis D, Tsavaris N, Kouroussis C, Aravantinos G, Agelakis S, Kakolyris S, Rigatos SK, Karabekios S and Georgoulias V: Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 12: 101-103, 2001.
18. Alberts SR, Townley PM, Goldberg RM, Cha SS, Morre Jr DF, Krook JE, Pilot HC, Fitch TR, Wiesonfeld M, Maillard JA and Sargent DJ: Gemcitabine and oxaliplatin for patients with advanced or pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study. Ann Oncol 13: 553-557, 2002.
19. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DJ and Benson AB: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma. Eastern Cooperative Oncology Group Trial E 2297. J Clin Oncol 20: 3270-3275, 2002.
20. Hess V, Salzberg M, Borner M, Marant R, Roth AD, Ludwig C and Hermann R: Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. J Clin Oncol 21: 66-68, 2003.
21. Stathopoulos GP, Rigatos SK, Dimopoulos MA, Giannakakis T, Fountzilas G, Kouroussis C, Janninis D, Aravantinos G, Androulakis N, Agelaki S. Stathopoulos JG and Georgoulias V: Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 14: 388-394, 2003.
22. Ulrich-Pur H, Raderer M, Verena Kornek G, Schull B, Schmid K, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang G and Scheithauer W: Irinotecan plus raltitrexed vs. raltitrexed alone in patients with gemcitabine pretreated advanced pancreatic adenocarcinoma. Br J Cancer 88: 1180-1184, 2003.
23. Rocha-Lima CM, Savarese D, Bruckner H, Dudet A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Mills LL and Green MR: Irinotecan plus gemcitabine induces both radiographic and CA-19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 20: 1182-1191, 2002.
24. Stathopoulos GP, Syrigos K, Polyzos A, Fountzilas G, Rigatos SK, Ziras N, Potamiannou A, Tsiakopoulos I, Androulakis N, Aravantinos G, Athanasiadis A, Papakotoulas P and Georgoulias V: Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine, an intergroup, multicenter phases II study. Ann Oncol 15: 224-229, 2004.
25. Stathopoulos GP, Syrigos K, Aravantinos G, Polyzos A, Papakotoulas P, Fountzilas G, Potamiannou A, Ziras N, Boukovinas J, Varthalitis J, Androulakis N, Kotaskis A, Samonis G and Georgoulias V: A multicenter phase III trial comparing irinotecan gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 95: 587-592, 2006.
26. Rocha-Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G and Miller LL: Irinotecan plus gemcitabine, results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22: 3776-3783, 2004.
27. Scheithauer W, Schüll B, Ulrich-Pur H, Schmid K, Raderer M, Haider K, Kwasney W, Depisch D, Schneeweiss B, Lang F and Kornek GV: Biweekly high dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic carcinoma: a randomized phase III trial. Ann Oncol 14: 97-104, 2003.
28. Rothenberg ML, Sharm A, Weiss GR, Villalona-Calero MA, Echardt JR, Aylesworth C, Kraynak MA, Rinaldi DA, Rodriguez GI, Burris III HA, Eckhardt SG, Stephens CD, Forral K, Nicol SJ and Von Hoff DD: Phase I trial of paclitaxel and gemcitabine administered every 2 weeks in patients with refractory solid tumors, Ann Oncol 9: 733-738, 1998.
29. Colluci G, Riccardi F, Giuliani F, Lopez M, Gebbia V, Uomo G, Biglietto M, Cigolari S, Borsellino N, Paoletti G, Maiello E and Gebbia N: Randomized trial of gemcitabine alone or with cisplatin in advanced pancreatic cancer: a phase II multicenter study of the Southern Italy Oncology Group. Proc Am Soc Clin Oncol 18: 250a (Abstract 961), 1999.
30. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Favoux R, Lepere C and de Gramont A: GemOx (gemcitabine + oxaliplatin) versus Gem (gemcitabine) in non resectable pancreatic adenocarcinoma: Final results of the GERCOR/GISCAD Intergroup phase III. J Clin Oncol 23: 3509-3516, 2005.
31. Oettle H, Richards DA, Ramanathom RK, van Laethem JL, Peeters M, Fuchs M, Zimmermann A, John W, Von Hoff D, Arning M and Kindler HL: A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer. Ann Oncol 16: 1639-1645, 2005.
32. Abou Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian NS, Feit K, Ackerman J, De Jager RL, Eckhardt GS and O'Reilly EM: A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer (APC). J Clin Oncol 24: 4441-4446, 2006.
33. Poplin E, Lewy DE, Berlin J, Rothenberg M, Cella D, Mitchell E, Alberts S and Benson A: Phase III trial of gemcitabine 30 minute infusion vs. gemcitabine fixed dose rate infusion versus gemcitabine + oxaliplatin. J Clin Oncol 24: 180s, 2006 (Abstract 4004).
34. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neuman H, Sarfan H, Humblet Y, Perez Ruixo J and Ma Y Von Hoff D: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22: 1430-1438, 2004.
35. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M and Buckels JA: A double-blind placebo-control, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first-line therapy in patients with advanced pancreatic cancer. Br J Cancer 87: 161-167, 2002.
36. Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet 363: 1049-1057, 2004.
37. Parkin DM, Bray FI and Devessa SS: Cancer burden in the year 2000, the global picture. Eur J Cancer 37: s4-s66, 2001.
38. Yamanaka Y, Friess H, Kobrin MS, Büchler M, Kunz J, Berger HG and Kore M: Overexpression of HER2/Neu oncogene in human pancreatic carcinoma. Hum Pathol 24: 1127-1134, 1993.
39. Safran H, Ianniti D, Ramanathan R, Schwartz JD, Steinhoff M, Nauman C, Hesketh P, Rathore R, Wolff R, Tantravahi U, Highes TM, Maia C, Pasquariello T, Goldstein L, King T, Tsai JY and Kennedy T: Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 22: 706-712, 2004.
40. Johnson SR and Leary A: Lapatinib, a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today 42: 441-453, 2006.
41. Baker CH, Solorzano CC and Fidler IJ: Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 62: 1996-2003, 2002.
42. De Gramont A and Van Cutsem E: Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small-cell lung, pancreatic and breast cancer. Oncology 69: 46-56, 2005.
43. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM and Vokes EE: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23: 8033-8040, 2005.
44. Yokoi K, Sasaki T, Bucana CD, Fan D, Baker CH, Kitadai Y, Kuwai T. Abbruzzese JL and Fidler IJ: Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res 65: 10371-10380, 2005.
45. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML and Sinicrope FA: Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroid anti-inflammatory drugs. Cancer Res 59: 4356-4362, 1999.
46. EL-Rayes BF, Zalupski MM, Shields AF, Ferris AM, Vaishampayan U, Heilbrun LK, Venkatramanamoorthy R, Adsay V and Philip PA: A phase II study of celecoxib gemcitabine and cisplatin in advanced pancreatic cancer. Invest New Drugs 23: 583-590, 2005.
47. Jasner R: Molecular regulation of pancreatic stellate cell function. Molecular Cancer 3: 1-8, 2004.
48. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F and Laurent-Puig P: KRAS mutations status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995, 2006.
49. Vivanco I and Sawyers CL: The phosphatidyl inositol 3 kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
50. Daucey JE: Therapeutic targets: mTOR and related pathways. Cancer Biol Ther 5: 1065-1073, 2006.
51. Hosshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J and Kohno M: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: 813-822, 1999.
52. Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, DeLuca P, Bruzek L, Piens J, Asbury P, Van Becelaere K, Herrera R, Sebolt-Leopold J and Meyer MB: Phase I and pharmacodynamic study of the oral MEK inhibitor CI-104 in patients with advanced malignancies. J Clin Oncol 23: 5281-5293, 2005.
53. Overholser JP, Prewett MC, Hooper AT, Waksal HW and Hicklin DJ: Epidermal growth factor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenografts in nude mice. Cancer 89: 74-82, 2000.
54. Huang ZQ, Buchsmaum DJ, Raisch KP, Bonner JA, Bland KI and Vickers SM: Differential responses by pancreatic carcinoma cell lines to prolonged exposure to erbitux (IMC-C225) anti-EGFR antibody. J Surg Res 111: 274-283, 2003.
55. Xiong HQ, Rosenberg A, Lobuglio A, Schmidt W, Wolff RA, Deutsch J, Needle M and Abbruzzese JL: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 22: 2610-2616, 2004.
56. Fjällskog MLH, Lejonklou MH, Öberg KE, Eriksson BK and Janson ET: Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 9: 1469-1473, 2003.
57. Tobita K, Kihima H, Dowaki S, Kashiwagi H, Ohtani Y, Oida Y, Yamazaki H, Nakamura M, Ueyama Y, Tanaka M, Inokuchi S and Makuuchi H: Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. Int J Mol Med 11: 305-309, 2003.
58. Veda S, Ogata S, Tsuda H, Kawarabayashi N, Kimura M, Sugiura Y, Tamai S, Matsubara O, Hatsuse K and Mochizuki H: The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 29: E1-E8, 2004.
59. Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R and Fidler IJ: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60: 2926-2935, 2000.
60. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos Th, Ptasynski M and Parulekar W: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966, 2007.